Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

197
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
197
Liver Regeneration01:24

Liver Regeneration

4.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

165
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

489
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
489
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

182
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
182

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexual dimorphism in the association of circulating TAM receptors-ligands with MASLD-related fibrosis.

JHEP reports : innovation in hepatology·2026
Same author

Residual bile flow shapes PPARγ-mediated antifibrotic responses in experimental segmental cholestasis.

Scientific reports·2026
Same author

An immunocompetent murine model of virus-elicited liver fibrosis and hepatocellular carcinoma.

Journal of hepatology·2026
Same author

Comparative Study of Chemically Induced Renal Mesenchymal and Mammary Tumors in Female Sprague-Dawley and Wistar Rats.

Toxicologic pathology·2026
Same author

Scar-associated endothelial-stellate cellular crosstalk drives fibrosis resolution in MASH.

Cell reports·2026
Same author

Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis.

Science translational medicine·2026
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K

Hepatic Fibrosis and Liver Cancer.

Aina Anton1,2, Scott Laurence Friedman2,3,4, Bruno Cogliati2,5

  • 1Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.

Seminars in Liver Disease
|December 30, 2025
PubMed
Summary
This summary is machine-generated.

Liver fibrosis, not just cirrhosis, can initiate liver cancer (hepatocellular carcinoma, HCC). Fibrosis remodels the liver microenvironment, promoting inflammation and immune suppression, driving cancer development even before cirrhosis.

More Related Videos

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.8K
A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.7K

Related Experiment Videos

Last Updated: Jan 7, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.8K
A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.7K

Area of Science:

  • Hepatology
  • Oncology
  • Immunology
  • Gastroenterology

Background:

  • Hepatocellular carcinoma (HCC) often arises in fibrotic livers, with cirrhosis as a known risk factor.
  • Emerging evidence indicates that liver fibrosis, particularly with metabolic dysfunction-associated steatotic liver disease (MASLD), can drive hepatocarcinogenesis independently of cirrhosis.
  • Hepatic stellate cells (HSCs) and the tumor microenvironment play critical roles in this process.

Purpose of the Study:

  • To review the mechanistic insights linking liver fibrosis to hepatocellular carcinoma (HCC) initiation.
  • To explore the roles of hepatic stellate cell (HSC) biology and tumor immunology in fibrosis-driven hepatocarcinogenesis.
  • To highlight how fibrosis creates a pre-malignant niche that promotes HCC development.

Main Methods:

  • This review synthesizes current literature on hepatic stellate cell (HSC) biology and tumor immunology.
  • Mechanistic insights into extracellular matrix (ECM) remodeling, immune surveillance reprogramming, and metabolic crosstalk are discussed.
  • The role of aging and cellular senescence in amplifying pro-tumorigenic signaling is examined.

Main Results:

  • Fibrotic liver remodeling increases ECM stiffness, disrupts liver architecture, and promotes abnormal angiogenesis.
  • Hepatic stellate cells (HSCs) reprogram the immune microenvironment, leading to immune cell exclusion and immunosuppression.
  • Aging and senescence exacerbate fibrosis-associated inflammation and immune dysfunction, reinforcing stemness and therapy resistance.

Conclusions:

  • Fibrosis acts as a critical instigator of HCC by creating a permissive microenvironment for malignant transformation.
  • The interplay between fibrogenic signaling, immune dysregulation, and metabolic factors drives HCC development.
  • Understanding these mechanisms reveals potential therapeutic targets for HCC prevention and treatment.